The in vitro effect of hydroxychloroquine on skin morphology in psoriasis

International Journal of Dermatology

Volumn 38, Issue 2, 1999, Pages 154-157

  Wolf, Ronni ^a   Lo Schiavo, Ada ^a   Lombardi, Maria Luisa ^a   De Angelis, Francesca ^a   Ruocco, Vincenzo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ARTICLE; CASE REPORT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KERATINIZATION; PSORIASIS; SKIN EXAMINATION;

ANTIMALARIALS; CULTURE TECHNIQUES; DERMIS; EPIDERMIS; HUMANS; HYDROXYCHLOROQUINE; KERATINOCYTES; KERATINS; MELANINS; PSORIASIS; SKIN;

EID: 0032980174     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00574.x     Document Type: Article

References (21)

1. Winkelmann RK, Perry HO, Achor RWP, Kirby TJ. Cutaneous syndromes produced as side effects of triparanol therapy. Arch Dermatol 1963; 87: 372-377.
2. Wolf R, Shechter H, Brenner S. Research models for psoriasis: "Great Expectations". Int J Dermatol 1995; 34: 448-455.
3. Proksch E, Feingold KR, Mao-Qiang M, Elias PM. Barrier function regulates epidermal DNA synthesis. J Clin Invest 1991; 87: 1668-1673.
4. Proksch E, Holleran WM, Menon GK, et al. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol 1993; 128: 473-482.
5. Williams ML, Elias PM. From the basket weave to barrier. Unifying concepts for the pathogensis of the disorders of cornification. Arch Dermatol 1993; 129: 626-629.
6. Eyre RW, Krueger GG. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity. Br J Dermatol 1982; 106: 153-159.
7. Fisher DA, Elias PM, LeBoit P. Exacerbation of psoriasis by the hypolipidemic agent gemfibrozil. Arch Dermatol 1988; 124: 854-855.
8. Feingold KR, Mao-Qiang M, Procksch E, et al. The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 1991; 96: 201-209.
9. Epidermal lipids and scaling diseases of the skin. Semin Dermatol 1992; 11: 169-176.
10. Petzold DG, Braun-Falco O, Wenig KH. Effect of plastic-foil-occlusion on psoriatic lesions. Arch Klin Exp Dermatol 1970; 238: 160-168.
11. Friedman SJ. Managment of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987; 123: 1046-1052.
12. David M, Lowe NJ. Psoriasis therapy: comparative studies with hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989; 21: 511-514.
13. Wolf R, Brenner S. Antimalarials and drug induced psoriasis. Malta Derm '94, Malta, November 9-12, 1994.
14. Wolf R, Lo Schiavo A. Is transglutaminase the mediator between antimalarial drugs and psoriasis? Int J Dermatol 1997; 36: 10-13.
15. Wolf R, Lo Schiavo A, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase. Int J Dermatol 1997; 36: 704-707.
16. Kadunce DP, Krueger GG. Pathogensis of psoriasis. Dermatol Clin 1995; 13: 723-737.
17. Ruocco V, de Angelis E, Lombardi ML, Pisani M. In vitro acantholysis by captopril and thiopronine. Dermatologica 1988; 176: 115-123.
18. De Angelis E, Lombardi ML, Grassi M, Ruocco V. Enalapril: a powerful in vitro non-thiol acantholytic agent. Int J Dermatol 1992; 31: 722-724.
19. Hohl D, Huber M, Frenk E. Analysis of the cornified cell envelope in lamellar ichthyosis. Arch Dermatol 1993; 129: 618-624.
20. Ruocco V, De Angelis E, Lombardi LM. Drug-induced pemphigus. II. Pathomechanisms and experimental investigations. Clin Dermatol 1993; 11: 507-513.
21. Menon GK, Feingold KR, Mao-Qiang M, et al. Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis. J. Invest Dermatol 1992; 98: 209-219.